Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
Related Questions
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you provide vitamin B12 supplementation to a patient on pemetrexed therapy if their B12 levels are normal or high?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
In a patient with potentially resectable lung cancer experiencing severe pain due to chest wall invasion, would you consider palliative radiation therapy prior to neoadjuvant/perioperative chemoimmunotherapy?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
